Sec Form 4 Filing - GADICKE ANSBERT @ TCR2 THERAPEUTICS INC.

Insider filing report for Changes in Beneficial Ownership

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

Here is the list of insider trading transaction codes

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Expires:

November 30, 2011

Estimated average burden hours per response...

0.5

1. Name and Address of Reporting Person

GADICKE ANSBERT

2. Issuer Name and Ticker or Trading Symbol
TCR2 THERAPEUTICS INC. [ TCRR]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X __ Director	X __ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O MPM CAPITAL, 450 KENDALL STREET

3. Date of Earliest Transaction (MM/DD/YY)
02/19/2019

(Street)

CAMBRIDGE, MA02142

4. If Amendment, Date Original Filed (MM/DD/YY)

6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (MM/DD/YY)	2A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/19/2019		C		79,644	A		79,644	I	See Footnote ^{( 2 )}
Common Stock	02/19/2019		C		52,469	A		52,469	I	See Footnote ^{( 3 )}
Common Stock	02/19/2019		C		146,447	A		146,447	I	See Footnote ^{( 4 )}
Common Stock	02/19/2019		C		2,195,681	A		2,195,681	I	See Footnote ^{( 5 )}
Common Stock	02/19/2019		C		351,155	A		351,155	I	See Footnote ^{( 6 )}
Common Stock	02/19/2019		C		2,421,775	A		2,421,775	I	See Footnote ^{( 7 )}
Common Stock	02/19/2019		C		9,291	A		88,935	I	See Footnote ^{( 2 )}
Common Stock	02/19/2019		C		5,247	A		57,716	I	See Footnote ^{( 3 )}
Common Stock	02/19/2019		C		17,085	A		163,532	I	See Footnote ^{( 4 )}
Common Stock	02/19/2019		C		256,163	A		2,451,844	I	See Footnote ^{( 5 )}
Common Stock	02/19/2019		C		35,115	A		386,270	I	See Footnote ^{( 6 )}
Common Stock	02/19/2019		C		282,540	A		2,704,315	I	See Footnote ^{( 7 )}
Common Stock	02/19/2019		P		1,373,333	A	$ 15	1,569,235	I	See Footnote ^{( 9 )}

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**
( *e.g.* , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (MM/DD/YY)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (MM/DD/YY)	3A. Deemed Execution Date, if any (MM/DD/YY)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			493,306	^{( 1 )}	^{( 1 )}	Common Stock	79,644	^{( 1 )}	0	I	See Footnote ^{( 2 )}
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			325,002	^{( 1 )}	^{( 1 )}	Common Stock	52,469	^{( 1 )}	0	I	See Footnote ^{( 3 )}
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			907,073	^{( 1 )}	^{( 1 )}	Common Stock	146,447	^{( 1 )}	0	I	See Footnote ^{( 4 )}
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			13,599,621	^{( 1 )}	^{( 1 )}	Common Stock	2,195,681	^{( 1 )}	0	I	See Footnote ^{( 5 )}
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			2,174,998	^{( 1 )}	^{( 1 )}	Common Stock	351,155	^{( 1 )}	0	I	See Footnote ^{( 6 )}
Series A Preferred Stock	^{( 1 )}	02/19/2019		C			15,000,000	^{( 1 )}	^{( 1 )}	Common Stock	2,421,775	^{( 1 )}	0	I	See Footnote ^{( 7 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			57,552	^{( 8 )}	^{( 8 )}	Common Stock	9,291	^{( 8 )}	0	I	See Footnote ^{( 2 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			32,500	^{( 8 )}	^{( 8 )}	Common Stock	5,247	^{( 8 )}	0	I	See Footnote ^{( 3 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			105,825	^{( 8 )}	^{( 8 )}	Common Stock	17,085	^{( 8 )}	0	I	See Footnote ^{( 4 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			1,586,623	^{( 8 )}	^{( 8 )}	Common Stock	256,163	^{( 8 )}	0	I	See Footnote ^{( 5 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			217,500	^{( 8 )}	^{( 8 )}	Common Stock	35,115	^{( 8 )}	0	I	See Footnote ^{( 6 )}
Series B Preferred Stock	^{( 8 )}	02/19/2019		C			1,750,000	^{( 8 )}	^{( 8 )}	Common Stock	282,540	^{( 8 )}	0	I	See Footnote ^{( 7 )}

**Reporting Owners**
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
GADICKE ANSBERT C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE, MA02142	X	X

**Signatures**
/s/ Ansbert Gadicke		02/21/2019
Signature of Reporting Person		Date

Explanation of Responses:

( 1 )Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
( 2 )The reported securities are owned directly by MPM Asset Management Investors BV2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 3 )The reported securities are owned directly by MPM Asset Management Investors SunStates Fund LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 4 )The reported securities are owned directly by MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 5 )The reported securities are owned directly by MPM BioVentures 2014, L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014, L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 6 )The reported securities are owned directly by MPM SunStates Fund, L.P. MPM SunStates Fund GP LLC is the general partner of MPM SunStates Fund, L.P. MPM SunStates GP Managing Member LLC is the managing member of MPM SunStates Fund GP LLC. The Reporting Person is a member of MPM SunStates Fund GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 7 )The reported securities are held directly by UBS Oncology Impact Fund, L.P. The general partner of UBS Oncology Impact Fund, L.P. is Oncology Impact Fund (Cayman) Management L.P. The general partner of Oncology Impact Fund (Cayman) Management L.P. is MPM Oncology Impact Management LP. The general partner of MPM Oncology Impact Management LP is MPM Oncology Impact Management GP LLC. The Reporting Person is the managing director of MPM Oncology Impact Management GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
( 8 )Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
( 9 )The reported securities are owned directly by MPM Asset Management LLC. The Reporting Person is a member of MPM Asset Management LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Sec Form 4 Filing - GADICKE ANSBERT @ TCR2 THERAPEUTICS INC. - 2019-02-19